Anika Therapeutics, Inc. (ANIK)

Nasdaq Stock Exchange
USD
US0352551081
4 May 1993  –  30 January 2023

Performance

Annualized Return
7.01%
Sharpe Ratio
0.46
Maximum Drawdown
-95.88%

Metrics

Metric Anika Therapeutics, Inc.
Initial Balance $10,000
Final Balance $75,175
Returns   [View more details]
Month-To-Date 1.59%
Year-To-Date 1.59%
3M 5.14%
6M 28.72%
Annual Return (3Y) -11.19%
Annual Return (5Y) -15.11%
Annual Return (All) 7.01%
Risk   [View more details]
Annual Volatility 69.95%
Max Drawdown -95.88%
Sharpe Ratio 0.46
Sortino Ratio 0.69
Adjusted Sortino (S/√2) 0.49

  • Initial balance: The amount of starting capital used to invest in the asset or portfolio. In this case, we're starting with a $10,000 investment on May 1993.
  • Final balance: The amount of capital we've accrued over time as of January 2023.
  • Annual return: Also known as annualized return, or CAGR (Compound Annual Growth Rate), measures how much an investment has increased on average each year, during a specific time period. The time period in this case is approximately 30 year(s). Even a small difference in return can have a big impact on the final balance over a long period of time.
  • Annual volatility: Basically indicates how much, in percentage points, the investment can deviate from its annual return, under most circumstances. An investment with an annual return of 5% and an annual volatility of 10% would indicate returns from approximately -5% to 15% most of the time. A lower volatility is usually preferred to ensure more steady returns over time.
  • Best year: The best performance attained over its lifetime in a given year.
  • Worst year: The worst performance undergone over its lifetime in a given year.
  • Max drawdown: The largest percentage drop from a peak to a trough of an asset or portfolio, before a new peak is attained. Maximum drawdown is an indicator of downside risk over a specified time period.
  • Sharpe Ratio: The Sharpe ratio measures the performance of an investment compared to a risk-free asset, after adjusting for its risk. A Sharpe Ratio above 1 is considered good.
  • Sortino Ratio: The Sortino Ratio is a variation of the Sharpe ratio that only penalizes the investment for negative volatility/outcomes, and not for positive volatility. A Sortino Ratio above 1 is considered good.
  • Adjusted Sortino Ratio: Sortino Ratio/√2. To allow for comparing the Sortino ratio to the Sharpe ratio, we multiply the risk measure of the Sortino ratio by the square root of 2 (which is the same as dividing the Sortino ratio by the square root of 2).
  • Ulcer Index: The Ulcer Index (UI) is a technical indicator that measures downside risk in terms of both the depth and duration of price declines.
  • Gain to Pain Ratio: The sum of all returns divided by the absolute value of the sum of all negative returns. In essence, the GPR shows the ratio of net returns to the losses incurred in getting those returns.

Annualized Returns

Annual Return 1y Annual Return 3y Annual Return 5y Annual Return 10y Annual Return 20y Annual Return
Anika Therapeutics, Inc. -3.97% -11.19% -15.11% 10.97% 18.32% 7.01%

Annual Returns

Year Anika Therapeutics, Inc.
1993 11.73%
1994 -58.04%
1995 106.67%
1996 -3.23%
1997 148.35%
1998 -42.28%
1999 31.4%
2000 -88.94%
2001 27.99%
2002 -1%
2003 883.84%
2004 -6.06%
2005 27.76%
2006 13.52%
2007 9.65%
2008 -79.11%
2009 150.99%
2010 -12.58%
2011 46.93%
2012 1.43%
2013 283.9%
2014 6.76%
2015 -6.33%
2016 28.3%
2017 10.11%
2018 -37.66%
2019 54.27%
2020 -12.71%
2021 -20.84%
2022 -17.39%
2023 1.59%

Anika Therapeutics, Inc. had 18 positive years and 13 negative years. That's a positive ratio of 58%.

Monthly Returns

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YTD
1993 0% 0% 0% 0% -18.8% -7.7% -8.3% 13.6% -24% 10.5% -9.5% 88.2% 57.3%
1994 -16.1% -13.3% -3.8% -20% -10% 13.9% 14.6% -6.4% -4.5% -14.3% -22.2% 7.1% -43.6%
1995 0% 10% 15.1% 10.5% -11.9% 0% 24.3% -8.7% 19% -8% -0% 34.8% 103.9%
1996 0% 3.2% -3.1% 4.8% 47.7% -4.2% -10.9% -0% 12.2% -19.6% -8.1% -11.8% 30.6%
1997 40% -0% 2.4% 9.3% 0% 19.1% -1.8% 21.8% -0.7% -0.8% -1.5% 14.6% 107.9%
1998 -22.2% 18.1% 13.9% 14.8% 5% 24.5% -2.2% -22.2% 18% -58.6% -11.5% 11.7% 8.3%
1999 -8.7% -1.9% 9.1% -4.8% 7.5% 58.1% -17.6% -10.7% -10% 5.6% 5.3% 13% 44.9%
2000 0.9% 34.2% -7.8% -12.1% -67.7% -30% -7.1% 7.7% -14.3% -2.1% -23.4% -30.6% -126.9%
2001 76% -9.1% -25% 60% -11.8% -0.2% -12.1% -9.5% -14.3% 4.5% 1% 5.3% 81.7%
2002 12.1% -5.4% 8.5% -3.5% 25.2% -17.3% -26.1% 41.2% -9.2% 3.8% -5.4% -7.5% 32.8%
2003 9.1% 38.9% 5.3% 58.9% 26.7% -0.9% 36.8% 26.5% 3.7% 18.1% 28.7% 13.4% 260.6%
2004 4.2% -8.4% -10.9% 14.2% 49.7% 22.2% -14.3% -12.2% 5.8% -19.4% -15% -3.2% 20.7%
2005 -3% 36.3% 5.8% 15.4% 2% -23.7% 9.2% 1.2% -6.9% 4.4% -4.3% -1% 42.6%
2006 -13.9% 36.2% -10.9% -5.9% -8.5% -8% 20.9% 16% -1.8% -4.8% -0.6% 5.2% 24.3%
2007 2.2% -0.6% -8.2% 4.6% 5.1% 11.7% 31.5% -8.7% 14.2% -9.7% -25.2% 3.4% 21.4%
2008 -24.5% 9.5% -29.5% 1.3% 1.3% -1.3% -5.2% 4.8% -15.4% -15% -43% -13.1% -131.5%
2009 34.2% -16.2% 34.2% 22% -9.8% -5.9% 21.6% 3.9% 8.3% 12.6% 9.4% -4.7% 120.5%
2010 -17.3% -0.8% 13.6% -0.9% -12.6% -4.4% 0.2% -16.1% 21.4% 6.5% -4.5% 9.2% -6.8%
2011 4.2% 30.2% -1% -7.4% -14.7% 0.6% -9.7% -6.9% -9.1% 10.8% 33% 22.2% 57.1%
2012 -6.1% 23.5% 10.4% 36% -20.3% -0.1% -10.6% 17% 5.7% -25.4% 5.5% -16% 18%
2013 6.8% 17.2% 16.6% -8.1% 10.6% 15.2% 18.3% 15.1% 3.2% 25% 15% 11.1% 149.8%
2014 -12.8% 18.3% 4.4% 4% 9.6% -1.1% -9.2% -0.1% -12.7% 9.5% 1.9% -0.4% 21.5%
2015 -3.8% 1.9% 3.1% -17.1% -1.1% -2.1% 14.7% -6.6% -10.1% 21% 8.9% -9.1% -0.5%
2016 -1.4% 20% -0.9% 2.1% 3.6% 13.4% -7% -5.4% 1.3% -7.3% 5.2% 4.9% 29.6%
2017 3.2% -7.4% -7.2% 6.2% 0.3% 6.6% 3.7% 5% 8% -5.8% 0.9% -2.2% 12.3%
2018 23.8% -22% -4.5% -11.5% -7.6% -21.3% 25.1% 3.4% 1.9% -15.2% -3.7% -2.4% -26.3%
2019 13% -14.1% -7.3% 5.3% 19.3% 6.9% 35.6% 3% -3.3% 28.2% -17.9% -10.3% 58.1%
2020 -20.7% 1.6% -30.8% 14.9% 0.9% 12.5% -3.5% 5.3% -7.7% -7.8% 15.9% 19.7% 5.7%
2021 -18.2% -0.8% 11.1% -1.5% 16.1% -7.2% -7.3% 7.5% -1.3% -2.1% -6.1% -8.4% -15.7%
2022 -11.2% 2.2% -22.7% -14.3% 1% 2.7% 4.7% -3.3% 5.3% 19.4% 11% -6.2% -9.8%
2023 1.6% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1.8%
Pos 51.7% 55.2% 48.3% 58.6% 60% 44.8% 46.7% 53.3% 46.7% 46.7% 43.3% 50% 74.2%
Avg 1.8% 6.9% -0.7% 6.1% 1.2% 2.5% 3.6% 2.5% -0.6% -1.2% -2% 4.6% 30.7%

Other Return Metrics

Metric Anika Therapeutics, Inc.
Cumulative Return 651.75%
Enh Ann Return 22.9%
Best Year 883.84%
Worst Year -88.94%
Best Month 88.17%
Worst Month -67.74%
Best Day 41.67%
Worst Day -65.52%
Win Ratio (Yearly) 58.06%
Win Ratio (Quarterly) 54.17%
Win Ratio (Monthly) 50.42%
Win Ratio (Daily) 49.5%

Annual Volatility

Annual Volatility 1y Annual Volatility 3y Annual Volatility 5y Annual Volatility 10y Annual Volatility 20y Annual Volatility
Anika Therapeutics, Inc. 42.95% 48.67% 52.98% 47.87% 56.15% 69.95%

Sharpe Ratio

Sharpe Ratio 1y Sharpe Ratio 3y Sharpe Ratio 5y Sharpe Ratio 10y Sharpe Ratio 20y Sharpe Ratio
Anika Therapeutics, Inc. 0.12 0 -0.04 0.46 0.58 0.46

3-Year Rolling Sharpe Ratio

The rolling Sharpe Ratio gives a clue about the continued consistency or stability of the risk-adjusted returns.

Drawdown Periods

Simply said, a drawdown is the "pain" period experienced by an investor between a peak (new highs) and subsequent valley (a low point before moving higher). In the table below are the fifth largest drawdowns encountered for the portfolio/asset in question.

Anika Therapeutics, Inc.

start valley end Drawdown days
1998-07-15 2000-12-26 2007-07-25 -95.88% 3297
2007-09-24 2008-12-30 2013-08-01 -86.24% 2138
2019-10-28 2022-05-09 - -72.19% 1190
1993-05-21 1994-12-16 1996-05-06 -68.42% 1081
2018-01-30 2018-06-20 2019-10-25 -57.96% 633

The Anika Therapeutics, Inc. took approximately 56 months on average to recover from a major drawdown. The longest drawdown lasted 110 months.

Underwater plot

The underwater plot shows you the drawdown periods on a chart. Whereas the performance chart usually gives you a positive viewpoint, the underwater plot gives you a pessimistic viewpoint. It helps you to visualize downtrends that occurred and how long it took for the portfolio's value to rebound to hit a new high after suffering a loss.

Other Risk Metrics

Metric Anika Therapeutics, Inc.
Sharpe Ratio 0.46
Sortino Ratio 0.69
Adjusted Sortino (S/√2) 0.49
Calmar Ratio 0.07
Omega Ratio 0.07
Gain to Pain Ratio 0.1
Winckel Ratio 51.61
Ulcer Index 0.52
Kelly Criterion 4.41%
Skew 0.16
Kurtosis 21.51
End of: